FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. PMID 42246654 · N Engl J Med · 2026-Jun-05 The record describes a Phase III randomized trial of obinutuzumab in primary membranous nephropathy, which is not an oncology condition. The primary efficacy endpoint is complete remission at week 104 (a categorical endpoint), not a time-to-event endpoint like OS, PFS, or DFS. Therefore, it does not meet the core eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention. PMID 42240800 · Intern Emerg Med · 2026-Jun-04 The record describes a systematic review of randomized phase 3/4 trials of direct oral anticoagulants (DOACs) for secondary prevention of venous thromboembolism (VTE) in non-cancer patients. The primary endpoint is symptomatic recurrent VTE, which is not an oncology time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The study population is non-cancer, and the disease is not a human malignant neoplasm. Therefore, it is excluded based on non-oncology. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early vs. delayed primary local therapy and survival in de novo metastatic prostate cancer: target trial emulation. PMID 42240667 · World J Urol · 2026-Jun-04 The record describes an observational target trial emulation of a non-drug intervention (primary-directed local therapy) for metastatic prostate cancer. It is not a randomized trial, and it does not involve a drug-containing intervention as defined by the criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS. PMID 42234958 · Blood Adv · 2026-Jun-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
B
|
影子组漏检补回 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis. PMID 42234870 · JNCI Cancer Spectr · 2026-Jun-03 The record is a systematic review and meta-analysis of Phase 3 RCTs, not an original primary report of a single trial. It reports safety incidence (peripheral edema) and does not include a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety of low lipoprotein(a) levels: the FOURIER trial. PMID 42234492 · Eur Heart J · 2026-Jun-03 This is a secondary safety analysis from a cardiovascular outcomes trial (FOURIER), not a primary report of oncology efficacy. The study is not oncology-focused, and while it includes malignancy as a safety outcome, malignancy is not the primary or key secondary efficacy endpoint. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort focused on drug intervention efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). PMID 42234197 · J Neurol · 2026-Jun-03 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam. PMID 41997039 · Eur J Cancer · 2026-Jun-03 The record is a randomized trial with a time-to-event oncology endpoint (prostate cancer mortality) and reports original results. However, it fails the drug-intervention criterion because the intervention is PSA screening, not a drug. Therefore, it is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open pancreaticoduodenectomy in patients with periampullary carcinoma: A randomised clinical trial. PMID 42262773 · J Minim Access Surg · 2026-Jun-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effects of argipressin on intraoperative fluid administration in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC): study protocol of a randomised clinical trial (HiPress Trial). PMID 42229964 · BMJ Open · 2026-Jun-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial. PMID 42228944 · Anesth Analg · 2026-Jun-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Sentinel Node Biopsy in the Neck Management of cN0 Sinonasal Squamous Cell Carcinoma: A Multicenter Pilot Trial on Safety and Feasibility. PMID 42228262 · Ann Surg Oncol · 2026-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary Analysis of the INSPIRE Cluster Randomized Trials. PMID 42268612 · JAMA Netw Open · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study. PMID 42226295 · World J Surg Oncol · 2026-Jun-01 The record describes a retrospective, multicenter study developing a prognostic biomarker (FSL score) and a nomogram. While the underlying data came from a randomized controlled trial, this publication is not a formal result report of that trial's intervention. It is a secondary, biomarker-focused analysis, and the drug intervention is not the subject of this efficacy evaluation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 42225990 · Nat Med · 2026-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer. PMID 42223796 · Adv Ther · 2026-Jun-01 The record describes a real-world retrospective cross-sectional survey of treatment patterns, not a randomized clinical trial. It is not a primary result report of a Phase III/IIIb or Phase II/III randomized trial with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis. PMID 42175549 · Cancer · 2026-Jun-01 While the study is from a randomized oncology trial with a drug intervention and analyzes time-to-event data, it is explicitly a secondary, post-hoc biomarker subgroup analysis, not the original primary or definitive report of the trial's main efficacy results. The phase is also not explicitly confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3. PMID 42159085 · Cancer · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial. PMID 42043827 · JAMA Intern Med · 2026-Jun-01 The trial is eligible for oncology and human subjects but is excluded because it is a cancer screening trial (not a treatment trial), the intervention is a screening modality (not a drug), and the primary efficacy endpoint is a proportion (screening participation), not a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial. PMID 41973444 · JAMA Intern Med · 2026-Jun-01 The study is an oncology-related randomized trial involving patients with hepatocellular cancer (part of the ESLD population), but it does not meet the required criteria for inclusion. The intervention is non-drug (palliative care delivery model), and the primary endpoint is quality-of-life, not a time-to-event efficacy endpoint. Mortality is reported but only as a secondary outcome with no time-to-event analysis specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial. PMID 41685810 · Int J Cancer · 2026-Jun-01 Trial is oncology-focused, randomized, with a drug intervention and primary results. However, it is not explicitly a Phase III/IIIb trial (phase not stated in abstract; mesh terms do not include 'Phase 3'), and crucially, the primary endpoints are incidence-based outcomes (HSIL recurrence and HPV persistence) reported as proportions and rates, not time-to-event endpoints with Kaplan-Meier curves or hazard ratios. Therefore, it fails the required time-to-event efficacy endpoint criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| EHealth intervention for quality of life in long-term breast cancer survivors: randomized controlled trial. PMID 41581214 · J Natl Cancer Inst · 2026-Jun-01 The study is an oncology randomized trial reporting on quality of life, not a time-to-event efficacy endpoint. It lacks a drug intervention and is not a Phase III/IIIb or Phase II/III trial. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades. PMID 41460153 · Int J Cancer · 2026-Jun-01 The record is a retrospective analysis of regulatory data on multiple oncology drug approvals. It does not meet the inclusion criteria for a single, original, formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. The study design is a review of multiple trials, not a trial report itself. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial. PMID 41352689 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 The record is a randomized controlled trial in human oncology (rectal cancer) evaluating a drug intervention (CapeOX vs capecitabine) with a primary time-to-event endpoint (3-year DFS). It reports definitive long-term results and is not an interim, subgroup, or safety-only analysis. Phase III is not explicitly stated but the trial is described as a definitive, multicenter, randomized controlled trial with a large sample size (n=505) and definitive primary endpoint, qualifying as a definitive phase trial under the criteria. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Treatment Effect of Beta-Blocker Therapy After Acute Myocardial Infarction With Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Trial Sequential Analysis. PMID 42473525 · Cureus · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. PMID 42416477 · Pleura Peritoneum · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| 18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial. PMID 42377125 · Radiology · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study. PMID 42341255 · JCO Precis Oncol · 2026-Jun While the record describes an analysis of a randomized comparison in oncology, it is a secondary, biomarker-driven analysis from a real-world study (FLEX), not a primary result from a definitive Phase III/IIIb or Phase II/III randomized trial. The parent trial's phase is not confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes: A target trial emulation study. PMID 42340940 · PLoS Med · 2026-Jun The study is an observational cohort study emulating a trial of statins for primary cardiovascular disease prevention in older adults with type 2 diabetes. It is not an oncology study, not a randomized trial, and does not involve a drug intervention for cancer. While it reports time-to-event outcomes (CVD, all-cause mortality), these are not the required cancer-specific endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study. PMID 42339511 · Cancer Med · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. PMID 42339309 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. PMID 42335416 · Am Soc Clin Oncol Educ Book · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. PMID 42317205 · Hemasphere · 2026-Jun Meets all eligibility criteria: oncology, human, Phase III, randomized, drug intervention, time-to-event primary endpoint, original result report. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 3 Panel · risk visible |
| Effects of Acceptance and Commitment Therapy on Death Anxiety in Cancer Survivors: A Randomized Controlled Trial. PMID 42317021 · Psychooncology · 2026-Jun The study is a randomized controlled trial in cancer survivors, but it evaluates a psychotherapy (ACT), not a drug-containing intervention. The primary endpoint is death anxiety, a quality-of-life measure, not a time-to-event efficacy endpoint (e.g., OS, PFS). It is not a Phase III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mindfulness-Based Stress Reduction for Breast Cancer Survivors (MBSR[BC]) Improves Self-Reported Optimism. PMID 42316845 · Psychooncology · 2026-Jun The study is an oncology RCT in human breast cancer survivors with original results. However, it is excluded because: 1) The intervention is non-pharmacological (MBSR), not a drug-containing intervention. 2) The endpoints are psychosocial outcomes, not time-to-event efficacy endpoints. 3) The trial phase is not established as Phase III or definitive. 4) The analysis is described as secondary/exploratory. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial. PMID 42272346 · United European Gastroenterol J · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China. PMID 42256683 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France). PMID 42256682 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. PMID 42253638 · EJHaem · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China. PMID 42242853 · Asia Pac J Clin Nutr · 2026-Jun The study is an oncology randomized Phase III trial with primary results, but it does not meet the inclusion criteria because the intervention is a non-drug nutritional product (FSMP) and the primary endpoint is not a time-to-event efficacy measure (it is a change in a biochemical marker). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial. PMID 42225102 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Personalised and Gamified Digital Decision Aid for Colorectal Cancer Screening: A Randomised Controlled Pilot Study. PMID 42216438 · Cancer Med · 2026-Jun This is a randomized pilot study of a digital decision aid for colorectal cancer screening, not a drug intervention trial, and does not have a time-to-event efficacy endpoint. It fails the core eligibility criteria of having a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of an internal traction device in colorectal endoscopic submucosal dissection: a multicenter randomized controlled trial. PMID 42191957 · Surg Endosc · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. PMID 42187551 · NEJM Evid · 2026-Jun Meets all eligibility criteria: oncology RCT in humans, Phase III (implied by definitive adjuvant trial with survival endpoints), drug intervention, time-to-event efficacy endpoints reported, and original final results. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Effects of Fospropofol on intraoperative hemodynamics in patients undergoing Supratentorial tumor resection: A randomized controlled trial. PMID 42176429 · J Clin Anesth · 2026-Jun The study is a randomized, human, oncology trial with a drug intervention (fospropofol vs. propofol) and original results. However, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcome is a hemodynamic measure (area under the threshold for mean arterial pressure <65 mmHg), and secondary outcomes are other perioperative clinical measurements, not oncology efficacy endpoints. Phase is not specified as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Postmastectomy Radiotherapy With Immediate Implant Reconstruction: Treatment Fractionation, Implant Plane, and Clinical Outcomes. PMID 42173060 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials. PMID 42161782 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Covered self-expandable metal stents in benign biliary strictures caused by chronic pancreatitis: a randomized controlled trial of 6 versus 12 months of stenting. PMID 42151467 · Surg Endosc · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials. PMID 42144019 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study. PMID 42144018 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |